Table 2.
EC50 and EC80 values for HepG2 cells and THP-1 monocytes. The third row per drug depicts the viability of the respective cell type after a 24 h exposure to the indicated concentration of the iDILI drug, expressed as% of the vehicle control activity.
| Drug | Concentration | THP-1 | HepG2 |
|---|---|---|---|
| TGZ | EC50 | 42 μM | 40 μM |
| EC80 | 27 μM | 34 μM | |
| Used conc. (32 μM) | ∼70% | ∼85% | |
| TVX | EC50 | 60 μM | 370 μM |
| EC80 | 23 μM | 100 μM | |
| Used conc. (25 μM) | ∼76% | ∼92% | |
| DcL | EC50 | 76 μM | 775 μM |
| EC80 | 30 μM | 604 μM | |
| Used conc. (125 μM) | ∼30% | ∼100% | |
| KC | EC50 | 12 μM | 24 μM |
| EC80 | 7 μM | 18 μM | |
| Used conc. (20 μM) | ∼20% | ∼80% | |